1. Home
  2. THRD vs BYON Comparison

THRD vs BYON Comparison

Compare THRD & BYON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • THRD
  • BYON
  • Stock Information
  • Founded
  • THRD 2019
  • BYON 1997
  • Country
  • THRD United States
  • BYON United States
  • Employees
  • THRD N/A
  • BYON N/A
  • Industry
  • THRD Biotechnology: Pharmaceutical Preparations
  • BYON Catalog/Specialty Distribution
  • Sector
  • THRD Health Care
  • BYON Consumer Discretionary
  • Exchange
  • THRD Nasdaq
  • BYON Nasdaq
  • Market Cap
  • THRD 512.9M
  • BYON 450.6M
  • IPO Year
  • THRD 2022
  • BYON N/A
  • Fundamental
  • Price
  • THRD $13.93
  • BYON $6.22
  • Analyst Decision
  • THRD Strong Buy
  • BYON Buy
  • Analyst Count
  • THRD 3
  • BYON 9
  • Target Price
  • THRD $20.33
  • BYON $17.13
  • AVG Volume (30 Days)
  • THRD 184.1K
  • BYON 3.1M
  • Earning Date
  • THRD 11-07-2024
  • BYON 10-24-2024
  • Dividend Yield
  • THRD N/A
  • BYON N/A
  • EPS Growth
  • THRD N/A
  • BYON N/A
  • EPS
  • THRD N/A
  • BYON N/A
  • Revenue
  • THRD N/A
  • BYON $1,476,271,000.00
  • Revenue This Year
  • THRD N/A
  • BYON N/A
  • Revenue Next Year
  • THRD N/A
  • BYON $3.58
  • P/E Ratio
  • THRD N/A
  • BYON N/A
  • Revenue Growth
  • THRD N/A
  • BYON N/A
  • 52 Week Low
  • THRD $5.82
  • BYON $6.06
  • 52 Week High
  • THRD $16.94
  • BYON $37.10
  • Technical
  • Relative Strength Index (RSI)
  • THRD 54.76
  • BYON 27.65
  • Support Level
  • THRD $11.69
  • BYON $6.12
  • Resistance Level
  • THRD $14.64
  • BYON $6.56
  • Average True Range (ATR)
  • THRD 0.99
  • BYON 0.58
  • MACD
  • THRD -0.04
  • BYON -0.15
  • Stochastic Oscillator
  • THRD 67.67
  • BYON 2.99

About THRD Third Harmonic Bio Inc.

Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.

About BYON Beyond Inc.

Beyond Inc is an online retailer that provides products and services through websites. The company offers a broad range of products, including furniture, décor, area rugs, bedding and bath, home improvement, outdoor, and kitchen and dining items, BMMG (like books, magazines, CDs), electronics, and other items. The home and garden product line accounts for a material part of its total revenue. The company operates through a direct business that makes sales from the company's own inventory, and a partner business that sells merchandise from manufacturers, distributors, and other suppliers through the company's websites. The company generates the majority of its total revenue from partner business in terms of business format, and from the U.S. in terms of market.

Share on Social Networks: